Objective: To determine the ocular hypotensive efficacy and safety of dorzolamide when
added to brimonidine or timolol in patients with uncontrolled primary open-angle glaucoma
(POAG).
Patients and Methods: This is a 1-year prospective open-label clinical trial of 48 consecutive POAG patients with inadequate intraocular pressure (IOP) control while using brimonidine
0.2% (23 patients) and timolol 0.5% (25 patients), 2 times daily. Patients were assigned
to receive dorzolamide 2% as adjunctive therapy, added 3 times daily to brimonidine
or timolol. IOP was measured on week 2, and months 3, 6, 9, and 12.
Results: A significant reduction in IOP from the baseline was observed after dorzolamide
use in both groups at visits during that year (P < 0.001). Overall, mean IOP reduction was
5.6 ± 1.9 mmHg with the brimonidine-dorzolamide combination, and 6.8 ± 1.7 mmHg with
timolol-dorzolamide after 1 year of treatment; the difference was significant (P = 0.029). No
statistical differences existed between the groups for adverse events (P < 0.05).
Conclusion: The addition of dorzolamide to brimonidine or timolol has significant IOPlowering efficacy during 1 year in patients with POAG whose IOPs were inadequately controlled
with brimonidine or timolol alone. The IOP-lowering effect of the timolol-dorzolamide
combination at 1 year was more pronounced than brimonidine-dorzolamide. Both combinations
were well-tolerated by the patients.
